Details

Autor(en) / Beteiligte

• Campbell, Joshua D
• Alexandrov, Anton
• Kim, Jaegil
• Wala, Jeremiah
• Berger, Alice H
• Pedamallu, Chandra Sekhar
• Shukla, Sachet A
• Guo, Guangwu
• Brooks, Angela N
• Murray, Bradley A
• Imielinski, Marcin
• Hu, Xin
• Ling, Shiyun
• Akbani, Rehan
• Rosenberg, Mara
• Cibulskis, Carrie
• Ramachandran, Aruna
• Collisson, Eric A
• Kwiatkowski, David J
• Lawrence, Michael S
• Weinstein, John N
• Verhaak, Roel G W
• Wu, Catherine J
• Hammerman, Peter S
• Cherniack, Andrew D
• Getz, Gad
• Artyomov, Maxim N
• Schreiber, Robert
• Govindan, Ramaswamy
• Meyerson, Matthew

Titel

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

Ist Teil von

• Nature genetics, 2016-06, Vol.48 (6), p.607-616

Ort / Verlag

New York: Nature Publishing Group US

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Matthew Meyerson, Ramaswamy Govindan and colleagues examine the exome sequences and copy number profiles of 660 lung adenocarcinoma and 484 lung squamous cell carcinoma tumors. They identify novel significantly mutated genes and amplification peaks and find that around half of the tumors have at least five predicted neoepitopes. To compare lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SqCC) and to identify new drivers of lung carcinogenesis, we examined the exome sequences and copy number profiles of 660 lung ADC and 484 lung SqCC tumor–normal pairs. Recurrent alterations in lung SqCCs were more similar to those of other squamous carcinomas than to alterations in lung ADCs. New significantly mutated genes included PPP3CA , DOT1L , and FTSJD1 in lung ADC, RASA1 in lung SqCC, and KLF5 , EP300 , and CREBBP in both tumor types. New amplification peaks encompassed MIR21 in lung ADC, MIR205 in lung SqCC, and MAPK1 in both. Lung ADCs lacking receptor tyrosine kinase–Ras–Raf pathway alterations had mutations in SOS1 , VAV1 , RASA1 , and ARHGAP35 . Regarding neoantigens, 47% of the lung ADC and 53% of the lung SqCC tumors had at least five predicted neoepitopes. Although targeted therapies for lung ADC and SqCC are largely distinct, immunotherapies may aid in treatment for both subtypes.